JTJinzhou Tian

Jinzhou Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinzhou Tian has a total of 245 co-authors. Here are the top co-authors by number of shared publications:

  • Jing Shi

    Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, National Center of Medicine (Brain Disorders), Beijing, China

    28 shared publications
  • Mingqing Wei

    Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    23 shared publications
  • Jingnian Ni

    Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    21 shared publications
  • Ting Li

    Department of Neurology, Dongzhimen Hospital Beijing University of Chinese Medicine Beijing China

    20 shared publications
  • Jing Shi

    Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    15 shared publications
  • Yongyan Wang

    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

    14 shared publications

Latest Publications

  • Open Access

    Temporal Mapping of CSVD ‐Related White Matter Lesions and Concurrent Neurovascular Dysfunction in Spontaneously Hypertensive Rats

    by Jing Peng, Jingnian Ni, Fuyao Li, Ting Li, Mingqing Wei, Tianci Ge, Lulu Yao, Jing Shi, Jinzhou Tian

    Objective: To define the critical onset window and mechanisms of white matter lesions (WMLs) in cerebral small vessel disease based on spontaneously hypertensive rat (SHR). Methods: SHRs and age‐matched Wistar‐Kyoto (WKY) rats were assessed from 20 to 36 weeks of age. Systolic blood pressure, beam‐walking performance, and magnetic resonance imaging (MRI)‐based white matter changes were evaluated at 4‐week intervals. At each time point, randomly selected animals were euthanized for histological analysis. Gait performance and novel object recognition were further assessed at 36 weeks of age. Additional histopathological, neurovascular, neuroinflammatory, transcriptomic, proteomic, and biochemical analyses were performed at the identified critical time point. Results: SHRs developed sustained hypertension and early small‐vessel morphological alterations from 20 weeks, followed by corpus callosum demyelination at 28 weeks and motor, gait, and non‐spatial memory deficits by 36 weeks. MRI identified 28 weeks as the onset of detectable white matter microstructural impairment, marked by reduced fractional anisotropy, axial diffusivity, and increased radial diffusivity. At this stage, histological and molecular analyses confirmed myelin disruption, altered mature oligodendrocyte (OL)‐ and oligodendrocyte precursor cell (OPC)‐associated marker profiles, microvascular rarefaction, blood–brain barrier disruption, and inflammation in SHRs. Transcriptomic analysis highlighted cAMP pathway dysregulation, whereas proteomic analysis identified Pde10a as a significantly upregulated candidate protein. Suppression of downstream cAMP/PKA/CREB signaling was further supported by biochemical validation. Conclusions: WMLs emerge at 28 weeks in SHRs and are accompanied by convergent neurovascular injury and inflammatory activation. Pde10a‐associated cAMP signaling may represent a candidate mechanism associated with hypertension‐related WML development in CSVD.

  • Open Access

    Traditional Chinese medicine: a promising whole-process management for Alzheimer’s disease

    by Lulu Yao, Jingnian Ni, Mingqing Wei, Ting Li, Fuyao Li, Jing Shi, Jinzhou Tian

    Was not provided for this article.


  • Perspective on strengthening dementia prevention and control system: a comprehensive framework for national health

    by Bin Cong, Hengge Xie, Yongan Sun, Jingnian Ni, Jing Shi, Mingqing Wei, Fuyao Li, Huali Wang, Luning Wang, Bin Qin, et al.


  • Open Access

    Effect of Bazi Bushen Capsule on D‐Galactose‐Induced Human Endothelial Cell Senescence Through PI3K/Akt/eNOS Signaling Pathway

    by Lulu Yao, Fuyao Li, Jingnian Ni, Mingqing Wei, Ting Li, Jing Shi, Jinzhou Tian

    Objectives: BaZi BuShen capsule (BZBS) is a Chinese herbal prescription with the function of nourishing the kidney, replenishing essence, and combating aging. This study aims to investigate the effects of BZBS on aging endothelial cells and to elucidate the underlying mechanisms.Methods: An aging human brain microvascular endothelial cells (HBMECs) model was established using D‐galactose (D‐gal) for 24 h. The efficacy of the model was evaluated by the positive rate of senescence‐associated β‐galactosidase (SA‐β‐Gal) staining. The treatment was administered using drug‐containing serum of BZBS. The experimental groups comprised the following: Control, Model, and groups treated with drug‐containing serum at low (BZBSL), medium (BZBSM), and high (BZBSH) doses of BZBS, in addition to a pathway inhibitor group (LY294002 [5 μM/L]). Western blotting and immunofluorescence assays were conducted to evaluate the expression levels of proteins. Nitric oxide (NO) levels in the cells were detected using an Assay Kit. The experiments were independently repeated five times.Results: D‐gal significantly elevated the SA‐β‐Gal positive rate in HBMECs. Intervention with BZBS significantly reduced the percentage of SA‐β‐Gal positive cells (p < 0.001). Compared to the Model group, drug‐containing serum of BZBS significantly increased the expression levels of PI3K, p‐Akt, Akt, and eNOS (p < 0.010) and elevated NO levels in the cells (p < 0.010), by which BZBS ameliorated HBMECs aging and enhanced the function of aging HBMECs.Conclusions: Our findings indicate that BZBS can mitigate D‐gal‐induced aging in HBMECs by activating the PI3K/Akt/eNOS signaling pathway.


  • Androgen deprivation therapy and dementia risk: An updated and dose-response meta-analysis

    by Shun Zhu, Jingnian Ni, Siwei Long, Yuou Teng, Yirou Yao, Jing Shi, Jinzhou Tian

    Background: The association between androgen deprivation therapy (ADT) and dementia risk is controversial, and the dose-response relationship between them remains unclear. Objective: We aim to further clarify the relationship between ADT and dementia risk. Methods: PubMed, Web of Science, Embase, and Cochrane Library databases were systematically searched up to September 2024 to identify relevant studies. A meta-analysis was conducted using hazard ratios (HR) and 95% confidence intervals (CI) as pooled indicators. The robust error meta-regression (REMR) approach was performed to explore the dose-response relationship. Heterogeneity was assessed using I² statistics, and subgroup analysis, sensitivity analysis, and meta-regressions were conducted. Publication bias was evaluated with a funnel plot and Egger's test. Results: Our meta-analysis of 21 studies involving 2,278,835 patients revealed that ADT significantly increased the risk of overall dementia (HR = 1.14, 95% CI: 1.06–1.20) and Alzheimer's disease (AD) (HR = 1.15, 95% CI: 1.06–1.23), but not non-AD dementia (HR = 1.01, 95% CI: 0.89–1.16). For ADT subtypes, anti-androgens increased the risk of overall dementia (HR = 1.27, 95% CI: 1.09–1.49), particularly for AD (HR = 1.53, 95% CI: 1.19–1.97), while Luteinizing hormone-releasing hormone therapy and bilateral orchiectomy were not linked to the risk of any dementia subtype. A bell-shaped non-linear relationship between ADT duration and dementia risk was observed, with the highest risk observed at 15.5 to 21.5 months (HR = 1.25), which was confirmed by subgroup analysis for AD. Conclusions: The risk of overall dementia and AD were found to be significantly associated with ADT in a bell-shaped dose-response effect.


  • Open Access

    Technical specification for developing a clinical practice guideline for the integration of traditional Chinese medicine and Western medicine

    by Jianxin Wang, Rui Sun, Fengwen Yang, Jianping Liu, Jiajie Yu, Yuanyuan Sun, Xuemin Gao, Boli Zhang, Junhua Zhang, Jinzhou Tian

    Developing a clinical practice guideline (CPG) for integrating traditional Chinese medicine (TCM) and Western medicine (WM) requires the accurate identification, collation, and integration of all available evidence on TCM and WM in a comprehensive, meaningful, and resource‐efficient manner. This entails framing appropriate clinical questions, retrieving and synthesizing evidence from multiple resources, and providing concise and complete recommendations for specific diseases. However, some existing CPGs for integrating TCM and WM lack deep and organic integration. As the effective preparation of a CPG for integrating TCM and WM typically involves a complex set of principles, methodology, and steps, we believe that a cohesive, step‐by‐step guide on how to prepare a CPG for integrating TCM and WM is essential. To facilitate the design and development of a robust CPG, we present a clear and concise methodology, outlining relevant principles and procedures, supported by references for guidance. This technical specification aims to simplify the methodology for preparing a CPG for integrating TCM and WM; provide healthcare professionals and researchers with methodologically sound tools; and enhance the quality of CPGs for integrating TCM and WM. This technical specification may help elucidate this complex process, facilitate evaluation of the quality of published CPGs for integrating TCM and WM, and improve the understanding and application of recommendations for the combined and integrated use of TCM and WM in a new system.


  • Association of Depression and Cognitive Performance in US Older Adults: A Secondary Analysis of Cross-Sectional Data Using NHANES 2013–2014

    by Lulu Yao, Jingnian Ni, Mingqing Wei, Ting Li, Ziyi Long, Jing Shi, Jinzhou Tian

    Introduction: Depression has been associated with cognitive performance, but whether sociodemographic and clinical characteristics might influence this association is not well elaborated. This study aimed to further explore this relationship in older adults. Methods: This cross-sectional study is based on data from the National Health and Nutrition Examination Survey (NHANES) 2013–2014. A total of 1,433 individuals with complete information on depressive symptoms and cognitive function variables were included in this study. Patient Health Questionnaire 9 (PHQ-9) score ≥10 as the cutoff to identify cases of depression in our study. We defined poor cognitive performance as a composite cognitive score <47. Logistic regression models were used to examine the association of depression with cognitive performance (model 1). We progressively adjusted the covariates as confounders (model 2: model 1 + age, and gender; model 3: model 2 + race, education level, family income, drinking, and smoking; model 4: model 3 + overweight, arthritis, hyperlipidemia, diabetes, hypertension, heart failure, coronary heart disease, heart attack, stroke, and cancer). We then conducted subgroup, interaction, and restricted cubic spline (RCS) analyses to examine this association. Results: The prevalence of poor cognitive performance was 36.6% (53/145) in the depression group and 14.1% (182/1,288) in the non-depression group. In the fully adjusted model, depression was significantly associated with poor cognitive performance (adjusted odds ratio: 2.25; 95% confidence interval: 1.31–3.81). The results were robust to sensitivity analyses. Gender and education level may modify the association between depression and poor cognitive performance. RCS analysis revealed that the PHQ-9 score was related to poor cognitive performance in a nonlinear manner (p for nonlinearity <0.001), and exhibited a J-shaped curve. Conclusion: Depression is associated with poor cognitive performance in US older adults. Early recognition and treatment of depression may be potential intervention strategies to protect cognitive health.


  • Open Access

    Comparative efficacy of various exercise interventions on sleep in patients with cognitive impairment: a systematic review and meta-analysis

    by Junlei Zhang, Yan Liu, Qingling Sun, Jing Shi, Jingnian Ni, Ting Li, Ziyi Long, Mingqing Wei, Jinzhou Tian

    Background: Sleep disturbances are an early indicator of cognitive impairment and exacerbate its progression. While pharmacological treatments for sleep disorders exist, their side-effect profile includes an increased risk of falls and the potential to exacerbate cognitive impairment. Non-pharmacological treatments such as physical exercise should be considered. However, uncertainties persist. We aimed to assess the potential benefits of exercise interventions on sleep in patients with cognitive impairment and determine the specific effects of various exercise modalities.Materials and methods: A systematic search was performed on seven databases for eligible studies published before Nov 2022. Randomized controlled trials of exercise for patients with cognitive impairment (mild cognitive impairment and Alzheimer’s disease) were included. All analyses were conducted using RevMan version 5.4. Meta-analysis and The Grading of Recommendations Assessment Development and Evaluations (GRADE) quality ratings were performed on sleep quality and objective sleep data.Results: A total of 8 randomized controlled trials were included with a sample size of 486 subjects. For patients with cognitive impairment, physical exercise had a beneficial effect on sleep quality [MD = −3.55 (−5.57, −1.32), Z = 3.13, p = 0.002] and total sleep time [MD = 33.77 (23.92, 43.62), Z = 6.72, P < 0.00001]. No improvement was found in sleep efficiency and nocturnal awakening time. Subgroup analysis showed that multi-component exercise produced superior results.Conclusion: Physical exercise may improve sleep quality and total sleep time for patients with cognitive impairment. Multi-component exercise designed individually is more effective. Large-scale randomized controlled trials with objective sleep outcome measurements are warranted.Clinical trial registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022377221.


  • Open Access

    Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

    by Yuchen Zhang, Jinzhou Tian, Jingnian Ni, Mingqing Wei, Ting Li, Jing Shi

    The pathogenesis associated with Alzheimer’s disease (AD) is particularly complicated, and early diagnosis and course monitoring of the disease are not ideal based on the available core biomarkers. As a biomarker closely related to neuroinflammation, YKL-40 provides a potential scalable approach in AD, but its association remains controversial and inconclusive with AD. We conducted this study to assess the utility of YKL-40 levels in peripheral blood and cerebrospinal fluid (CSF) of AD patients and healthy controls (HCs) by meta-analysis. We systematically searched and screened relevant trials for comparing YKL-40 levels between AD patients and HCs in PubMed, Embase, Cochrane, and Web of Science, with a search deadline of 14 March 2023 for each database. A total of 17 eligible and relevant studies involving 1811 subjects, including 949 AD patients and 862 HCs, were included. The results showed that YKL-40 levels in the peripheral blood of AD patients and HCs did not possess significant differences. Subgroup analysis showed YKL-40 significantly differed in plasma (SMD = 0.527, 95%CI: [0.302, 0.752]; p = 0.000), but did not in serum. In the case of comparison with HCs, YKL-40 was significantly higher in CSF of AD patients (SMD = 0.893, 95%CI: [0.665, 1.121]; p = 0.000). Besides that, when we performed a combined analysis of total YKL-40 in both peripheral blood and CSF, overall YKL-40 concentrations were also significantly increased among AD patients (SMD = 0.608, 95%CI: [0.272, 0.943]; p = 0.000). YKL-40 provides support and rationale for the neuroinflammatory pathogenesis of AD. The significance of CSF levels of YKL-40 for early screening of AD is definite. Plasma levels of YKL-40 also appear to assist in discriminating AD patients from HCs, which facilitates early screening and monitoring of the natural course of AD.